Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 228-783-6 | CAS number: 6358-69-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Dec 1976 to March 1977
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 978
- Report date:
- 1978
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- no
- Remarks:
- Study conducted prior to implementation of OECD GLP
Test material
- Reference substance name:
- Trisodium 8-hydroxypyrene-1,3,6-trisulphonate
- EC Number:
- 228-783-6
- EC Name:
- Trisodium 8-hydroxypyrene-1,3,6-trisulphonate
- Cas Number:
- 6358-69-6
- Molecular formula:
- C16H10O10S3.3Na
- IUPAC Name:
- trisodium 8-hydroxypyrene-1,3,6-trisulphonate
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Breeder Winkelmann, Borchen
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 32 - 35 days
- Weight at study initiation: males 87 - 92 g / females 80 - 82 g
- Fasting period before study: no information given
- Housing: individually in Macrolon type II cages
- Diet: ad libitum
- Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23 ± 2°C
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- DIET PREPARATION
- Rate of preparation of diet (frequency): weekly
- Mixing appropriate amounts with (Type of food): Altromin-R-powder
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 3 months
- Frequency of treatment:
- continuous
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 ppm
- Dose / conc.:
- 100 ppm
- Remarks:
- 8.34 mg/kg bw/day (males); 12.28 mg/kg bw/day (females)
calculated based on mean weekly food consumtion relating to mean body weight (week 15)
- Dose / conc.:
- 1 000 ppm
- Remarks:
- 81.40 mg/kg bw/day (males); 121.32 mg/kg bw/day (females)
calculated based on mean weekly food consumtion relating to mean body weight (week 15)
- Dose / conc.:
- 10 000 ppm
- Remarks:
- 849.28 mg/kg bw/day (males); 1245.05 mg/kg bw/day (females)
calculated based on mean weekly food consumtion relating to mean body weight (week 15)
- No. of animals per sex per dose:
- 15
- Control animals:
- yes, concurrent no treatment
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: after 4 weeks and at termination
- Anaesthetic used for blood collection: Not specified
- Animals fasted: Not specified
- How many animals: 5 males/5 females
- Parameters examined: haematocrit, haemoglobin concentration, erythrocyte count, MCH and MCV, total and differential leukocyte count, platelet count, and a measure of blood clotting time/potential.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: after 4 weeks and at termination
- Animals fasted: Not specified
- How many animals: 5 males/5 females
- Parameters examined: alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, bilirubin, total protein, glucose, total cholesterol,
URINALYSIS: Yes
- Time schedule for collection of urine: after 4 weeks and at termination
- Metabolism cages used for collection of urine: Not specified
- Animals fasted: Not specified
- Parameters examined: glucose, ketone bodies, bilirubin, total protein, urobilinogen, pH-value, sediment, urea, creatinine
NEUROBEHAVIOURAL EXAMINATION: No
IMMUNOLOGY: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- slight reduction of body weight development for male rats in the highest dose group
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- slight but significant and dose dependent increase in thromboplastin time for male rats in the mid and high dose groups.
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- slight decrease in bilirubin values for female rats in the high dose group after 4 weeks (no changes at termination).
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- - male rats showed significant and dose dependant lower absolute heart weights in all dose groups.
- male rats showed slight but significant lower testis weights in the high dose group - Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- sporadic findings in individual animals were:
- indications of inflamation in lung and liver (not specified)
- round cell infiltration in myocard of and in kindney one control rat respecitvely
- dilation of uterus (individual control and treated animals)
- atrophy of testis (one male high dose group) - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not specified
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 81.4 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 245.05 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: highest dose tested without adverse effects
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Any other information on results incl. tables
Male and female rats received pyranin doses of 0, 100, 1000 and 10,000 ppm, respectively, administered with the diet.
The animals fed in this way showed no treatment-related symptoms in any dose group during the entire experimental period. The growth of male rats in the dose groups up to 1000 ppm as well as the female rats of all treatment groups was unaffected. In the male rats, 10000 ppm resulted in a slight growth retardation in the second half of the experiment. There were no mortalities.
The significant and dose-dependent prolongation of thromboplastin concentrations in male rats of the experimental groups dosed with 1000 and 10.000 ppm in the blood test after 3 months are not considered to be an expression of a disturbance in the coagulation system since the differences to the control group are very small and all values were within the normal range for this rat strain. Thus the blood was not damaged by the treatment.
In the female animals of the high dose group group, the bilirubin values measured 4 weeks after the start of the experiment were also within the normal historical range (2s range 0.10 to 0.26 mg / 100 ml measured in 100 untreated female rats of the same age). Clinical-chemical analyzes, gross pathology, and histopathological examinations did not reveal any signs of treatment-induced liver damage.
Urine tests, concentrations of urea and creatinine in the serum as well as macroscopic and histopathological organ findings did not indicate any influence on the kidneys.
Blood glucose and cholesterol levels were not changed during treatment or at termination.
No treatment related changes were found in the gross pathological examination of all rats. The significantly lower cardiac and test weights in the male rats corresponded approximately to the somewhat lower body weights of the treatment groups and because there was no histopathological corelate they were not regarded as toxicologically relevant.
The results obtained during the histopathological examination do not exceed the usual extent for conventional rats and are not due to treatment with pyranine.
Doses up to 1000 ppm (81.4 mg/kg bw/day) were thus tolerated by the male rats, doses up to 10,000 ppm (1245.05 mg/kg bw/day) by the female rats without any adverse effects.
Applicant's summary and conclusion
- Conclusions:
- Doses up to 1000 ppm (81.4 mg/kg bw/day) were tolerated by the male rats, doses up to 10,000 ppm (1245.05 mg/kg bw/day) were tolerated by the female rats without any adverse effects.
- Executive summary:
Groups of 15 male and 15 female rats and 30 animals in each of the control groups received trisodium 8-hydroxypyrene-1,3,6-trisulphonate for 3 months administered with the diet in the following concentrations: 0 (control), 100, 1000, and 10,000 ppm.
Appearance, behavior, and mortality were unaffected in male and female rats receiving doses up to 1000 ppm. Doses up to 1000 ppm (81.4 mg/kg bw/day) in the male rats or up to 10,000 ppm (1245.05 mg/kg bw/day) in the female rats had no effect on the body weight gain.
In the highest dose group receiving 10,000 ppm (849.28 mg/kg bw/day) the body weight gain of the male rats was slightly delayed.
The blood was not damaged in the dose groups up to 10,000 ppm (849.28 mg/kg bw/day males/ 1245.05 mg/kg bw/day females).
According to the clinico-chemical, macroscopic-anatomical and histopathological studies, the male and female rats dosed with up to 10,000 ppm (849.28 mg/kg bw/day males/ 1245.05 mg/kg bw/day females) did not show any evidence for liver damage.
Urine tests, clinical-chemical analyzes, gross - and histopathological examinations did not provide any evidence for renal impairment in dose groups up to 10,000 ppm (849.28 mg/kg bw/day males/ 1245.05 mg/kg bw/day females).
Blood glucose and cholesterol concentrations were in the normal range in male and female rats up to the dose groups of 10,000 ppm (849.28 mg/kg bw/day males/ 1245.05 mg/kg bw/day females).
Gross pathology and histopathological examinations did not give any indications for treatment-related organ changes in dose groups up to 10,000 ppm (849.28 mg/kg bw/day males/ 1245.05 mg/kg bw/day females).
Doses of up to 1000 ppm (81.4 mg/kg bw/day) for male rats and up 10,000 ppm (1245.05 mg/kg bw/day) for female rats were tolerated without any effects under the conditions described in this study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.